WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011041512) COMPOSITIONS AND METHODS FOR TREATING MLV-INFECTION, AND PREVENTING AND TREATING MLV-INITIATED DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/041512    International Application No.:    PCT/US2010/050864
Publication Date: 07.04.2011 International Filing Date: 30.09.2010
IPC:
A61K 31/475 (2006.01), A61K 31/4745 (2006.01), A61K 31/4738 (2006.01), A61P 35/00 (2006.01)
Applicants: EMORY UNIVERSITY [US/US]; Office of Technology Transfer 1599 Clifton Road, 4th Floor Atlanta, GA 30322 (US) (For All Designated States Except US).
UNIVERSITY OF UTAH [US/US]; Technology and Commercialization Office 615 Arapeen #310 Salt Lake City, UT 84108 (US) (For All Designated States Except US).
SCHINAZI, Raymond, F. [US/US]; (US) (For US Only).
SINGH, Ila [US/US]; (US) (For US Only)
Inventors: SCHINAZI, Raymond, F.; (US).
SINGH, Ila; (US)
Agent: BRADIN, David; Intellectual Property/Technology Law PO Box 14329 Research Triangle Park, NC 27709 (US)
Priority Data:
61/314,385 16.03.2010 US
61/248,261 02.10.2009 US
Title (EN) COMPOSITIONS AND METHODS FOR TREATING MLV-INFECTION, AND PREVENTING AND TREATING MLV-INITIATED DISEASES
(FR) COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UNE INFECTION PAR MLV, ET PRÉVENTION ET TRAITEMENT DE MALADIES CAUSÉES PAR MLV
Abstract: front page image
(EN)Compositions and methods for inhibiting infection by XMRV or other MLV are disclosed. Also disclosed are methods for treating cancers resulting from infection by XMRV or other MLV, and for preventing such cancers. The anti- XMRV/anti-MLV compounds are predominantly integrase inhibitors, such as globoidnan A, L-000870812, S/GSK1349572, S/GSK1265744, Raltegravir and Elvitegravir, and also reverse transcriptase inhibitors AZT, tenofovir, and tenofovir DF. The compounds are also useful for treating chronic fatigue syndrome or other diseases with neuroimmune symptoms resulting from an infection by XMRV or other MLV. The compositions can also include other therapeutic agents known for treating prostate cancer, breast cancer, lymphomas, and leukemias, such as anti-androgenic agents, radioisotopes, and conventional anti-cancer compounds.
(FR)L'invention concerne des compositions et des méthodes destinées à inhiber l'infection par XMRV ou autres MLV. Elle concerne également des méthodes de traitement de cancers résultant de l'infection par XMRV ou autres MLV, et de prévention de tels cancers. Les compositions anti-XMRV/anti-MLV sont principalement des inhibiteurs de l'intégrase, tels que globoidnan A, L-000870812, S/GSK1349572, S/GSK1265744, Raltegravir et Elvitegravir, mais aussi des inhibiteurs de la transcriptase inverse (AZT), le ténofovir, et le ténofovir DF. Ces composés sont également utiles pour traiter le syndrome de fatigue chronique ou d'autres maladies présentant des symptômes neuro-immuns résultant d'une infection par XMRV ou autres MLV. Les compositions peuvent également comprendre d'autres agents thérapeutiques réputés traiter le cancer de la prostate, le cancer du sein, les lymphomes et les leucémies, tels que des agents anti-androgéniques, des radio-isotopes et des composés anticancéreux classiques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)